

# Kengo Nagashima

RESEARCH ASSISTANT PROFESSOR · BIOSTATISTICIAN

Department of Global Clinical Research, Graduate School of Medicine, Chiba University  
1-8-1 Inohana Chuo-ku, Chiba 260-8670, Japan

☎ +81-43-227-6507 | ✉ [nshi@chiba-u.jp](mailto:nshi@chiba-u.jp) | 🌐 [nshi.jp/en/](http://nshi.jp/en/) | 📱 [nshi-stat](https://www.instagram.com/nshi-stat)

## Research Interests

---

**Biostatistics** Survival Analysis, Meta-analysis, Biomarkers in Clinical Trials, Missing Data, Causal Inference

**Statistical Methodology** Semiparametric Models, Estimating Equations, Mixed Effect Models

## Education

---

### Tokyo University of Science

Tokyo, Japan

PH.D. IN ENGINEERING

April 2010–March 2014

Dissertation: “Statistical screening methods for pharmacokinetics-related genes in genome-wide studies”

### Tokyo University of Science

Tokyo, Japan

M.SC. IN ENGINEERING

April 2006–March 2008

Master’s Thesis: “A comparison of statistical methods for SNP association analysis under Hardy–Weinberg disequilibrium”

### Tokyo University of Science

Tokyo, Japan

B.SC. IN ENGINEERING

April 2002–March 2006

## Professional Positions

---

### Department of Global Clinical Research, Graduate School of Medicine, Chiba University

Chiba, Japan

RESEARCH ASSISTANT PROFESSOR

April 2015–present

### Clinical Research Center, Chiba University Hospital

Chiba, Japan

RESEARCH ASSISTANT PROFESSOR

April 2013–March 2015

### Faculty of Pharmaceutical Sciences, Josai University

Saitama, Japan

RESEARCH ASSOCIATE

April 2008–March 2013

## Publications (Peer-Reviewed)

---

### STATISTICAL METHODOLOGY

- 1 Nagashima K, Sato Y. Information criteria for Firth’s penalized partial likelihood approach in Cox regression models. *Statistics in Medicine* 2017; **36**(21): 3422–3436. DOI: [10.1002/sim.7368](https://doi.org/10.1002/sim.7368). [Preprint].
- 2 Noma H, Nagashima K. A note on the Mantel–Haenszel estimators when the common effect assumptions are violated. *Epidemiologic Methods* 2016; **5**(1): 19–35. DOI: [10.1515/em-2015-0004](https://doi.org/10.1515/em-2015-0004).
- 3 Nagashima K, Sato Y, Noma H, Hamada C. An efficient and robust method for analyzing population pharmacokinetic data in genome-wide pharmacogenomic studies: a generalized estimating equation approach. *Statistics in Medicine* 2013; **32**(27): 4838–4858. DOI: [10.1002/sim.5895](https://doi.org/10.1002/sim.5895).

4 Nagashima K, Sato Y, Hamada C. A modified maximum contrast method for unequal sample sizes in pharmacogenomic studies. *Statistical Applications in Genetics and Molecular Biology* 2011; **10**(1): Article 41. DOI: [10.2202/1544-6115.1560](https://doi.org/10.2202/1544-6115.1560).

5 Sato Y, Laird NM, Nagashima K, Kato R, Hamano T, Yafune A, Kaniwa N, Saito Y, Sugiyama E, Kim S-R, Furuse J, Ishii H, Ueno H, Okusaka T, Saijo N, Sawada J-i, Yoshida T. A new statistical screening approach for finding pharmacokinetics-related genes in genome-wide studies. *The Pharmacogenomics Journal* 2009; **9**(2): 137–146. DOI: [10.1038/tpj.2008.17](https://doi.org/10.1038/tpj.2008.17).

## CLINICAL RESEARCH METHODOLOGY

6 Gosho M, Sato Y, Nagashima K, Takahashi S. Trends in study design and the statistical methods employed in a leading general medicine journal. *Journal of Clinical Pharmacy and Therapeutics* 2017. *In press*. DOI: [10.1111/jcpt.12605](https://doi.org/10.1111/jcpt.12605).

7 Sato Y, Gosho M, Nagashima K, Takahashi S, Ware JH, Laird NM. Statistical methods in the *Journal* — an update. *New England Journal of Medicine* 2017; **376**(11):1086–1087. DOI: [10.1056/NEJMc1616211](https://doi.org/10.1056/NEJMc1616211). (Correspondence)

8 Gosho M, Nagashima K, Sato Y. Study designs and statistical analyses for biomarker research. *Sensors* 2012; **12**(7): 8966–8986. DOI: [10.3390/s120708966](https://doi.org/10.3390/s120708966). (Review)

## MEDICAL RESEARCHES

9 Yanai T, Iwasa S, Hashimoto H, Ohyanagi F, Takiguchi T, Takeda K, Nakao M, Sakai H, Nakayama T, Minato K, Arai T, Suzuki K, Shimada Y, Nagashima K, Terakado H, Yamamoto N. A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. *International Journal of Clinical Oncology* 2017. *In press*.

10 Sasaki Y, Iwasa S, Okazaki S, Goto M, Kojima Y, Naganuma A, Nagashima K, Nagai Y, Hirano H, Honma Y, Takashima A, Kato K, Hamaguchi T. A phase II study of combination therapy with oral S-1 and cisplatin in elderly patients with advanced gastric cancer. *Gastric Cancer* 2017. *In press*. DOI: [10.1007/s10120-017-0753-2](https://doi.org/10.1007/s10120-017-0753-2).

11 Iizumi S, Takashima A, Narita Y, Tajika M, Muro K, Kawai S, Yasui H, Matsushima T, Takahari D, Nagashima K, Boku N. Efficacy and safety of taxane-monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study. *Cancer Chemotherapy and Pharmacology* 2017; **80**(3): 575–582. DOI: [10.1007/s00280-017-3397-3](https://doi.org/10.1007/s00280-017-3397-3).

12 Shiraishi H, Fujiwara Y, Kakuya T, Tsuta K, Motoi N, Miura N, Watabe Y, Watanabe S-i, Noro R, Nagashima K, Huang W, Yamada T, Asamura H, Ohe Y, Honda K. Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma. *Biomarkers in Medicine* 2017; **11**(9): 721–731. DOI: [10.2217/bmm-2017-0150](https://doi.org/10.2217/bmm-2017-0150).

13 Honma Y, Hokamura N, Nagashima K, Sudo K, Shoji H, Iwasa S, Takashima A, Kato K, Hamaguchi T, Boku N, Ito Y, Itami J, Koyanagi K, Igaki H, Tachimori Y. Clinical outcomes of resectable esophageal cancer with supraclavicular lymph node metastases treated with curative intent. *Anticancer Research* 2017; **37**(7): 3741–3749. DOI: [10.21873/anticancer.11748](https://doi.org/10.21873/anticancer.11748).

14 Nishide A, Fujita M, Sato Y, Nagashima K, Takahashi S, Hata A. Income-related inequalities in access to dental care services in Japan. *International Journal of Environmental Research and Public Health* 2017; **14**(5): 524. DOI: [10.3390/ijerph14050524](https://doi.org/10.3390/ijerph14050524).

15 Shoji H, Heike Y, Tada K, Kitano S, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S, Takashima A, Kato K, Boku N, Honda K, Yamada T, Hamaguchi T. The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy. *Oncotarget* 2017. *In press*. DOI: [10.18632/oncotarget.18297](https://doi.org/10.18632/oncotarget.18297).

16 Fujita M, Sato Y, Nagashima K, Takahashi S, Hata A. Impact of geographic accessibility on utilization of the annual health check-ups by income level in Japan: A multilevel analysis. *PLoS ONE* 2017; **12**(5): e0177091. DOI: [10.1371/journal.pone.0177091](https://doi.org/10.1371/journal.pone.0177091).

17 Nomura K, Kido M, Tanabe A, Nagashima K, Takenoshita S, Ando K. Investigation of optimal weight gain during pregnancy for Japanese Women. *Scientific Reports* 2017; **7**(1): 2569. DOI: [0.1038/s41598-017-02863-1](https://doi.org/10.1038/s41598-017-02863-1).

- 18 Korematsu S, Nagashima K, Sato Y, Nagao M, Hasegawa S, Nakamura H, Sugiura S, Miura K, Okada K, Fujisawa T. "Spike" in acute asthma exacerbations during enterovirus D68 epidemic in Japan: A nation-wide survey. *Allergology International* 2017. *In press*. DOI: [10.1016/j.alit.2017.04.003](https://doi.org/10.1016/j.alit.2017.04.003).
- 19 Matsumura T, Terada J, Kinoshita T, Sakurai Y, Yahaba M, Ema R, Amata A, Sakao S, Nagashima K, Tatsumi K, Hiwasa T. Circulating anti-coatomer protein complex subunit epsilon (COPE) autoantibodies as a potential biomarker for cardio- and cerebro-vascular events in patients with obstructive sleep apnea. *Journal of Clinical Sleep Medicine* 2017; **13**(3): 393–400. DOI: [10.5664/jcsm.6488](https://doi.org/10.5664/jcsm.6488).
- 20 Koshizaka M, Ishikawa K, Ishikawa T, Kobayashi K, Takemoto M, Horikoshi T, Shimousa R, Takahashi S, Nagashima K, Sato Y, Tatsuno I, Terano T, Hashimoto N, Kuribayashi N, Uchida D, Yokote K, on behalf of the PRIME-V Study Investigators. Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in type 2 diabetes patients receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: A study protocol for a prospective, multicenter, blinded-endpoint phase IV randomized controlled trial (PRIME-V study). *BMJ Open* 2017; **7**(5): e015766. DOI: [10.1136/bmjopen-2016-015766](https://doi.org/10.1136/bmjopen-2016-015766).
- 21 Nishimura T, Iwasa S, Nagashima K, Okita N, Takashima A, Honma Y, Kato K, Hamaguchi T, Yamada Y, Shimada Y, Boku N. Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes. *Gastric Cancer* 2017; **20**(4): 655–662. DOI: [10.1007/s10120-016-0670-9](https://doi.org/10.1007/s10120-016-0670-9).
- 22 Yamamoto Y, Yamaguchi S, Sasho T, Fukawa T, Akatsu Y, Akagi R, Yamaguchi T, Takahashi K, Nagashima K, Takahashi K. Quantitative ultrasound elastography can quantify mechanical and histological tendon healing in a rabbit model of achilles tendon transection. *Radiology* 2017; **283**(2): 408–417. DOI: [10.1148/radiol.2016160695](https://doi.org/10.1148/radiol.2016160695).
- 23 Yamaguchi N, Misawa S, Sato Y, Nagashima K, Katayama K, Sekiguchi Y, Iwai Y, Amino H, Suichi T, Yokota T, Nishida Y, Kohara N, Hirata K, Nishiyama K, Yabe I, Kaida K-I, Suzuki N, Nodera H, Tsuji S, Koike H, Kira J-I, Hanaoka H, Kusunoki S, Kuwabara S, JET-GBS Group. A prospective, multi-center, randomized phase II study to evaluate the efficacy and safety of eculizumab in patients with Guillain-Barré syndrome (GBS): Japanese Eculizumab Trial for GBS (JET-GBS). *JMIR Research Protocols* 2016; **5**(4): e210. DOI: [10.2196/resprot.6610](https://doi.org/10.2196/resprot.6610).
- 24 Nishi T, Kitahara H, Fujimoto Y, Nakayama T, Sugimoto K, Nagashima K, Hanaoka H, Kobayashi Y. Efficacy of intravenous nicorandil for fractional flow reserve assessment: Study protocol for a crossover randomised trial. *BMJ Open* 2016; **6**(11): e012737. DOI: [10.1136/bmjopen-2016-012737](https://doi.org/10.1136/bmjopen-2016-012737).
- 25 Misawa S, Sato Y, Katayama K, Nagashima K, Aoyagi R, Sekiguchi Y, Sobue G, Koike H, Yabe I, Sasaki H, Watanabe O, Takashima H, Nishizawa M, Kawachi I, Kusunoki S, Mitsui Y, Kikuchi S, Nakashima I, Ikeda S-i, Kohara N, Kanda T, Kira J-i, Hanaoka H, Kuwabara S, for the Japanese POEMS Syndrome for Thalidomide (J-POST) Trial Study Group. Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial. *The Lancet Neurology* 2016; **15**(11): 1129–1137. DOI: [10.1016/S1474-4422\(16\)30157-0](https://doi.org/10.1016/S1474-4422(16)30157-0).
- 26 Tada K, Kitano S, Shoji H, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Yamada Y, Katayama N, Boku N, Heike Y, Hamaguchi T. Pretreatment immune status correlates with progression-free survival in chemotherapy-treated metastatic colorectal cancer patients. *Cancer Immunology Research* 2016; **4**(7): 592–599. DOI: [10.1158/2326-6066.CIR-15-0298](https://doi.org/10.1158/2326-6066.CIR-15-0298).
- 27 Sasaki Y, Akasu T, Saito N, Kojima H, Matsuda K, Nakamori S, Komori K, Amagai K, Yamaguchi T, Ohue M, Nagashima K, Yamada Y. Prognostic and predictive value of extended RAS mutation and mismatch repair status in stage III colorectal cancer. *Cancer Science* 2016; **107**(7):1006–1012. DOI: [10.1111/cas.12950](https://doi.org/10.1111/cas.12950).
- 28 Tanemura N, Uyama Y, Nagashima K, Suzuki T, Asahina Y, Kobayashi Y, Iyo M, Yokote K, Hanaoka H. Comparison of drug use between clinical practice and regulatory approval: results in older Japanese patients with rheumatoid arthritis, diabetes, high blood pressure, or depression. *Therapeutic Innovation & Regulatory Science* 2016; **50**(6): 743–750. DOI: [10.1177/2168479016648731](https://doi.org/10.1177/2168479016648731).

- 29 Yamaguchi T, Iwasa S, Nagashima K, Ikezawa N, Hamaguchi T, Shoji H, Honma Y, Takashima A, Okita N, Kato K, Yamada Y, Shimada Y. Comparison of panitumumab plus irinotecan and cetuximab plus irinotecan for KRAS wild-type metastatic colorectal cancer. *Anticancer Research* 2016; **36**(7): 3531–3536. URL: <http://ar.iiarjournals.org/content/36/7/3531>.
- 30 Fujita M, Sato Y, Nagashima K, Takahashi S, Hata A. Income related inequality of health care access in Japan: A retrospective cohort study. *PLoS ONE* 2016; **11**(3): e0151690. DOI: [10.1371/journal.pone.0151690](https://doi.org/10.1371/journal.pone.0151690).
- 31 Tawada A, Chiba T, Saito T, Ogasawara S, Suzuki E, Ooka Y, Arai M, Kanda T, Shinozaki M, Goto N, Nagashima K, Yokosuka O. Utility of prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with nucleos(t)ide analogues. *Oncology* 2016; **90**(4): 199–208. DOI: [10.1159/000444392](https://doi.org/10.1159/000444392).
- 32 Yamamoto Y, Yamaguchi S, Sasho T, Fukawa T, Akatsu Y, Nagashima K, Takahashi K. Quantitative ultrasound elastography with an acoustic coupler for achilles tendon elasticity: measurement repeatability and normative values. *Journal of Ultrasound in Medicine* 2016; **35**(1): 159–166. DOI: [10.7863/ultra.14.11042](https://doi.org/10.7863/ultra.14.11042).
- 33 Naito S, Tanaka J, Nagashima K, Chang B, Hishiki H, Takahashi Y, Oikawa J, Nagasawa K, Shimojo N, Ishiwada N. The impact of heptavalent pneumococcal conjugate vaccine on the incidence of childhood community-acquired pneumonia and bacteriologically confirmed pneumococcal pneumonia in Japan. *Epidemiology and Infection* 2016; **144**(3): 494–506. DOI: [10.1017/S0950268815001272](https://doi.org/10.1017/S0950268815001272).
- 34 Aoyagi R, Hamada H, Sato Y, Suzuki H, Onouchi Y, Ebata R, Nagashima K, Terauchi M, Terai M, Hanaoka H, Hata A, on behalf of the KAICA Trial investigators. Study protocol for a phase III multi-centre, randomized, open-label, blinded-endpoint trial to evaluate the efficacy and safety of immunoglobulin plus Cyclosporin A in patients with severe Kawasaki disease (KAICA Trial). *BMJ Open* 2015; **5**(12): e009562. DOI: [10.1136/bmjopen-2015-009562](https://doi.org/10.1136/bmjopen-2015-009562).
- 35 Fujita M, Sato Y, Nagashima K, Takahashi S, Hata A. Validity assessment of self-reported medication use by comparing to pharmacy insurance claims. *BMJ Open* 2015; **5**(11): e009490. DOI: [10.1136/bmjopen-2015-009490](https://doi.org/10.1136/bmjopen-2015-009490).
- 36 Iwasa S, Nagashima K, Yamaguchi T, Matsumoto H, Ichikawa Y, Goto A, Yasui H, Kato K, Okita N, Shimada Y, Yamada Y. S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies. *Cancer Chemotherapy and Pharmacology* 2015; **76**(3): 605–614. DOI: [10.1007/s00280-015-2834-4](https://doi.org/10.1007/s00280-015-2834-4).
- 37 Fujita M, Sato Y, Nagashima K, Takahashi S, Hata A. Predictive power of a body shape index for development of diabetes, hypertension, and dyslipidemia in Japanese adults: a retrospective cohort study. *PLoS ONE* 2015; **10**(6): e0128972. DOI: [10.1371/journal.pone.0128972](https://doi.org/10.1371/journal.pone.0128972).
- 38 Utsumi H, Honma Y, Nagashima K, Iwasa S, Takashima A, Kato K, Hamaguchi T, Yamada Y, Shimada Y, Kishi Y, Nara S, Esaki M, Shimada K. Bevacizumab and postoperative wound complications in patients with liver metastases of colorectal cancer. *Anticancer Research* 2015; **35**(4): 2255–2261. URL: <http://ar.iiarjournals.org/content/35/4/2255>.
- 39 Takahashi N, Yamada Y, Furuta K, Nagashima K, Kubo A, Sasaki Y, Shoji H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Hamaguchi T, Shimada Y. Association between serum ligands and the skin toxicity of anti-EGFR antibody in metastatic colorectal cancer. *Cancer Science* 2015; **106**(5): 604–610. DOI: [10.1111/cas.12642](https://doi.org/10.1111/cas.12642).
- 40 Nagashima K, Yanai T, Iwasa S, Ohyanagi F, Kasai T, Minato K, Sakai H, Sakamoto C, Takeda K, Harada D, Goto K, Yamamoto N. A double-blind randomized phase II study of olanzapine 10mg versus 5mg for highly emetogenic chemotherapy-induced emesis. *Japanese Journal of Clinical Oncology* 2015; **75**(2): 229–231. DOI: [10.1093/jjco/hyu191](https://doi.org/10.1093/jjco/hyu191).
- 41 Shirakawa T, Kato K, Nagashima K, Nishikawa A, Sawada R, Takahashi N, Shoji H, Sasaki Y, Honma Y, Iwasa S, Takashima A, Okita N, Hamaguchi T, Yamada Y, Shimada Y. A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy. *Cancer Chemotherapy and Pharmacology* 2014; **74**(6): 1207–1215. DOI: [10.1007/s00280-014-2597-3](https://doi.org/10.1007/s00280-014-2597-3).

Shoji H, Yamada Y, Taniguchi H, Nagashima K, Okita N, Takashima S, Honma Y, Iwasa S, Kato K, Hamaguchi T, Shimada Y.  
42 Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection. *Cancer Science* 2014; **105**(8): 1002–1007. DOI: [10.1111/cas.12453](https://doi.org/10.1111/cas.12453).

Iwasa S, Nakajima TE, Nagashima K, Honma Y, Kato K, Hamaguchi T, Yamada Y, Shimada Y. Lack of association of proteinuria  
43 and clinical outcome in patients treated with bevacizumab for metastatic colorectal cancer. *Anticancer Research* 2013; **33**(1):  
309–316. URL: <http://ar.iijournals.org/content/33/1/309>.

Horita Y, Yamada Y, Kato K, Hirashima Y, Akiyoshi K, Nagashima K, Nakajima TE, Hamaguchi T, Shimada Y. Phase II clinical trial  
44 of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial. *International Journal of  
Clinical Oncology* 2012; **17**(6): 604–609. DOI: [10.1007/s10147-011-0331-2](https://doi.org/10.1007/s10147-011-0331-2).

Okita NT, Esaki T, Baba E, Sakai D, Tokunaga S, Takiuchi H, Mizunuma N, Nagashima K, Kato K. A multicenter phase II study of  
45 the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer.  
*Investigational New Drugs* 2012; **30**(5): 2026–2031. DOI: [10.1007/s10637-011-9779-1](https://doi.org/10.1007/s10637-011-9779-1).

Fujie H, Niu K, Ohba M, Tomioka Y, Kitazawa H, Nagashima K, Ohru T, Numasaki M. A distinct regulatory role of Th17 cytokines  
46 IL-17A and IL-17F in chemokine secretion from lung microvascular endothelial cells. *Inflammation* 2012; **35**(3): 1119–1131.  
DOI: [10.1007/s10753-011-9419-0](https://doi.org/10.1007/s10753-011-9419-0).

Nakajima TE, Yoshida H, Okamoto N, Nagashima K, Taniguchi H, Yamada Y, Shimoda T, Masutomi K. Nucleostemin and TWIST  
47 as predictive markers for recurrence after neoadjuvant chemotherapy for esophageal carcinoma. *Cancer Science* 2012; **103**(2):  
233–238. DOI: [10.1111/j.1349-7006.2011.02142.x](https://doi.org/10.1111/j.1349-7006.2011.02142.x).

Tanai C, Nakajima TE, Nagashima K, Kato K, Hamaguchi T, Yamada Y, Muro K, Shirao K, Kunitoh H, Matsumura Y, Yamamoto S,  
48 Shimada Y. Characteristics and outcomes of patients with advanced gastric cancer who declined to participate in a  
randomized clinical chemotherapy trial. *Journal of Oncology Practice* 2011; **7**(3): 148–153. DOI: [10.1200/JOP.2010.000106](https://doi.org/10.1200/JOP.2010.000106).

Hashimoto K, Takashima A, Nagashima K, Okazaki S, Nakajima TE, Kato K, Hamaguchi T, Yamada Y, Shimada Y. Progression-free  
49 survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric  
cancer. *Journal of Cancer Research and Clinical Oncology* 2010; **136**(7): 1059–1064. DOI: [10.1007/s00432-009-0752-8](https://doi.org/10.1007/s00432-009-0752-8).

## Funding History

---

### **Practical research of blood biomarkers for predicting effects of postoperative adjuvant chemotherapies by metastatic activity analysis of non-small cell lung cancer**

Co-I

JAPAN AGENCY FOR MEDICAL RESEARCH AND DEVELOPMENT, PRACTICAL RESEARCH FOR INNOVATIVE CANCER CONTROL

April 2017–March 2020

### **Developing blood biomarkers for evaluating risks of early stage cancer by protein and peptide modification analysis**

Co-I

JAPAN AGENCY FOR MEDICAL RESEARCH AND DEVELOPMENT, PROJECT FOR CANCER RESEARCH AND THERAPEUTIC EVOLUTION (P-CREATE)

April 2017–March 2019

### **Gender specific optimal chemotherapy**

Co-I

JAPAN AGENCY FOR MEDICAL RESEARCH AND DEVELOPMENT, PROJECT FOR WHOLE IMPLEMENTATION TO SUPPORT AND ENSURE THE FEMALE LIFE—WISE

November 2016–March 2019

## Development of efficient screening method for early detection and risk stratification of pancreatic cancer

Co-I

JAPAN AGENCY FOR MEDICAL RESEARCH AND DEVELOPMENT, PRACTICAL RESEARCH FOR INNOVATIVE CANCER CONTROL

September 2016–March 2017

## Statistical inference for rare event data and its application in clinical researches

PI

JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE (JSPS) KAKENHI, GRANT-IN-AID FOR YOUNG SCIENTISTS (B)  
Grant number: 16K16014

April 2016–March 2019

## Teaching History

---

### Linear statistical inference

2 credits

GRADUATE SCHOOL OF ENGINEERING, TOKYO UNIVERSITY OF SCIENCE

Spring 2016–present

## Professional Activities

---

### PROFESSIONAL AFFILIATIONS

#### American Statistical Association

MEMBER

2011–present

#### The International Biometric Society

MEMBER

2008–present

### JOURNAL REVIEWER

#### Statistics Journal

STATISTICAL APPLICATIONS IN GENETICS AND MOLECULAR BIOLOGY

#### Medical Journal

NANOMEDICINE, JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

## Softwares

---

### pimeta Package

R PACKAGE: PREDICTION INTERVAL FOR RANDOM-EFFECTS META-ANALYSIS

2017

<https://github.com/nshi-stat/pimeta>

### ph2bayes Package

R PACKAGE: BAYESIAN SINGLE-ARM PHASE II DESIGNS; CRAN TASK VIEW: EXPERIMENTALDESIGN

2016

<https://cran.r-project.org/package=ph2bayes>

### %skmdata

SAS MACRO: A SAS MACRO FOR THE KAPLAN–MEIER PLOT WITH SGPLOT PROCEDURE

2015

<https://github.com/nshi-stat/skmdata>

### RcmdrPlugin.KMggplot2 Package

R PACKAGE: GG PLOT2 GUI FRONTEND, R COMMANDER PLUG-IN FOR DATA VISUALIZATION WITH 'GGPLOT2'

2012

<https://cran.r-project.org/package=RcmdrPlugin.KMggplot2>

### mmcm Package

R PACKAGE: MODIFIED MAXIMUM CONTRAST METHOD (NAGASHIMA K, ET AL. SAGMB 2011)

2009

<https://cran.r-project.org/package=mmcm>